SEC Form 4 · accession 0001354488-16-008247
TG THERAPEUTICS, INC. · TGTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael S Weiss
Officer — See Remarks · Director · 10% Owner
Period of report
Sep 1, 2016
Accepted (ET)
Sep 1, 2016 · 8:03 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001001316
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Sep 1, 2016 | G | 328,764 | $0.00 | D | 9,455,662 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This Form 4 is filed by Mr. Weiss to report the transfer of 328,764 shares of TG Therapeutics stock to the Weiss Family and Descendants Trust.
- F2Includes shares of restricted Common Stock, which vest over various time periods. Includes 33,334 warrants to purchase Common Stock at $2.25, exercisable through December 31, 2016. Finally, also included in Mr. Weiss' beneficial ownership are 4,499,560 shares of Common Stock and 410,450 warrants to purchase Common Stock at $2.48, exercisable through February 24, 2017 issued to Opus Point Partners, LLC, of which Mr. Weiss is a co-founder, managing partner, and principal and beneficially owns a 50% interest.
Remarks
Executive Chairman, Interim CEO and President